Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

Inflammatory Bowel Disease

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

J Crohns Colitis

Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR

doi: 10.1093/ecco-jcc/jjab093

Gallbladder and Biliary DiseasesHepatitisHepatology

Long-term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis

Clin Gastroenterol Hepatol.

Bowlus CL, Pockros PJ, Kremer AE, Parés A, Forman LM, Drenth JPH, Ryder SD, Terracciano L, Jin Y, Liberman A, Pencek R, Iloeje U, MacConell L, Bedossa P

doi: 10.1016/j.cgh.2019.09.050.

COMMENTED

Inflammatory Bowel Disease

Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study

★ 3 Recommended and commented by PD Dr Luc Biedermann, Faculty Member

J Crohns Colitis

Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G

doi: 10.1093/ecco-jcc/jjab012

COMMENTED

Esophagus Diseases

Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis

★ 3 Recommended and commented by Prof. Dr Stephan Vavricka, Faculty Member

doi: 10.1016/j.cgh.2020.03.036.

Gallbladder and Biliary DiseasesHepatology

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

J Hepatol.

Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, Shrestha R, Trotter J, Goldberg D, Rushbrook S, Hirschfield GM, Schiano T, Jin Y, Pencek R, MacConell L, Shapiro D, Bowlus CL, AESOP Study Investigators

doi: 10.1016/j.jhep.2020.02.033.

Inflammatory Bowel Disease

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial

J Intern Med.

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KE, Tveit KS, Lorentzen M, Berset IP, Fevang BT, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK

doi: 10.1111/joim.12880.

Gallbladder and Biliary DiseasesHepatology

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

Am J Gastroenterol.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC1, Hirschfield GM, Hansen BE, van Buuren HR

doi: 10.1038/ajg.2017.440.

Inflammatory Bowel Disease

IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease

J Crohns Colitis.

Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S

doi: 10.1093/ecco-jcc/jjz110.

Hepatitis

Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial

Am J Gastroenterol.

Yim HJ, Kim W, Ahn SH, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Han KH

doi: 10.14309/ajg.0000000000000605.

Related content

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

Long-term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis

Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study

Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease

Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial